Barclays
AKCA

Barclays’s Akcea Therapeutics Inc AKCA Stock Holding History

Barclays’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,334
Closed -$696K – 5297
2020
Q3 		$696K Buy
38,334
+4,388
+13% +$62.2K ﹤0.01% 2975
2020
Q2 		$465K Buy
33,946
+15,952
+89% +$246K ﹤0.01% 3395
2020
Q1 		$257K Sell
17,994
-492
-3% -$8.07K ﹤0.01% 4104
2019
Q4 		$312K Buy
18,486
+2,895
+19% +$53.9K ﹤0.01% 4692
2019
Q3 		$240K Buy
15,591
+7,568
+94% +$161K ﹤0.01% 4837
2019
Q2 		$188K Sell
8,023
-2,671
-25% -$66K ﹤0.01% 5171
2019
Q1 		$302K Buy
10,694
+4,294
+67% +$125K ﹤0.01% 4523
2018
Q4 		$193K Sell
6,400
-6,481
-50% -$182K ﹤0.01% 4600
2018
Q3 		$451K Sell
12,881
-1,484
-10% -$44.9K ﹤0.01% 4355
2018
Q2 		$340K Buy
14,365
+3,053
+27% +$72.9K ﹤0.01% 4285
2018
Q1 		$290K Buy
11,312
+8,934
+376% +$192K ﹤0.01% 4484
2017
Q4 		$41K Buy
2,378
+2,030
+583% +$39.8K ﹤0.01% 5876
2017
Q3 		$10K Buy
+348
New +$6.44K ﹤0.01% 6149

Barclays's AKCA Position: Q4 2020 in Review

Barclays sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 38,334 shares — an estimated $696K sold.

Barclays first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $696K in Q3 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Barclays reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Barclays sold 38,334 Akcea Therapeutics Inc shares in Q4 2020, an estimated $696K.
  • Barclays first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • Barclays's Akcea Therapeutics Inc position peaked at $696K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.